Clinical Trial Search

Primary: Number of Participants With Procedure Success — 121 Participants

Primary: Imaging Outcome (Powered): Minimal Stent Area (MSA) — 5.72; 5.36 mm^2 — p=<0.0001

Primary: Delta Cardiac Troponin I (ΔcTnI) — 0.04; 0.19 ng/mL

Primary: Clinical Success — 20 Participants

Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio

Primary: 30-day Composite Major Adverse Cardiac Event (MACE) — 256; 83 participants

Primary: Percentage of Participants With Clinical Procedural Success — 97.6 percentage of participants

Primary: Major Adverse Cardiac and Cerebrovascular Events — 23; 24 Participants

Primary: Clinical Procedural Success — 100 percentage of participants

Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…

Primary: Device Technical Success — 29 lesions

Primary: Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events — 3; 4; 4; 3…

Primary: Number of Participants With Clinical Success — 723 Participants

Primary: Number of Participants With Residual Ischemia (iFR <0.90) — 112 participants

Primary: Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose — 74.81; 31.77 percent inhibition — p=<0.0001

Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…

Primary: Number of Participants With Peri-procedural Myocardial Necrosis — 118; 122 Participants — p=<0.05

Primary: Major Adverse Cardiac Events — 2 percentage of event

Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter

Primary: First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events…

Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants

Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year

Primary: Short-termed Fractal Scaling Exponent (Alpha 1) — 0.01; -0.03 unit-less — p=0.34

Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56

Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…

Primary: MACCE — 80; 51 Participants — p=0.35

Primary: All Cause Mortality and Readmission at 30 Days. — 16; 28 participants — p=<0.05

Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90

Primary: Percentage of Adherent Patients — 590; 4484; 2209; 3633 Participants

Primary: Clinical Events Defined as the Composite of 30-day Death, MI, Repeat Revascularization, Catheter Thrombus, Stroke, Thrombocytopenia, Bailout Use of Glycoprotein IIb/IIIa…